# Sanofi India share price today (Sanofi India Ltd, NSE: SANOFI)

> Sanofi India share price today: ₹3,381.60 at the NSE close on 3 November 2026, down 29.3% in a year. Sanofi India (NSE: SANOFI) is worth ₹7,788 crore, trades at a P/E of 21.3 and has closed between ₹2,772.80 and ₹4,636.80 over the past 52 weeks. > Sanofi India Ltd's share price has fallen more than its earnings. Earnings per share fell 21.0% in a year while the price moved −29.3%. SANOFI · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/sanofi-india-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹3,381.60 (−29.3% in a year)
- P/E: 21.3× (lower than 56% of the last 10 years)
- Revenue (Sep 2026): ₹492 Cr (+3.6% on a year ago)
- Profit (Sep 2026): ₹117 Cr (+53.9% on a year ago)
- Operating margin: 33.0% (+5.0 points on a year ago)
- ROCE: 58%, FY25
- ROIC: 74.5%, against a 12.0% cost of capital: +62.5 points

The main question: domestic institutions moved −3.2 percentage points over 8 quarters while the business went the other way. ## What is the Sanofi India share price today? Sanofi India Ltd's share price was ₹3,381.60 at the close on 3 November 2026. It has been falling for 64 weeks. That is 3.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹2,773 and ₹4,637, and at that close it sat 33% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +26% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Sanofi India this quarter? Three changes stood out: indian funds and insurers (DIIs) cut their stake for 5 quarters in a row, best operating margin in 14 quarters and foreign funds (FIIs) raised their stake for 3 quarters in a row. 1. Indian funds and insurers (DIIs) cut their stake for 5 quarters in a row From 23.1% to 19.4% of the company by the September 2026 quarter. 2. Best operating margin in 14 quarters Operating margin was 33% in the September 2026 quarter, against 28% a year earlier. 3. Foreign funds (FIIs) raised their stake for 3 quarters in a row From 5.6% to 5.7% of the company by the September 2026 quarter. ## What are Sanofi India's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Sanofi India reported revenue of ₹492 crore, up 3.6% from ₹475 crore a year earlier, and a profit of ₹117 crore, up 53.9% from ₹76.0 crore. ### Sanofi India results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹492 crore | ₹475 crore | +3.6% |
| Profit | ₹117 crore | ₹76.0 crore | +53.9% |
| Earnings per share | ₹50.74 | ₹33.04 | +53.6% |
| Operating margin | 33.0% | 28.0% | +5.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 5 August 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Sanofi India share price history? Sanofi India closed at ₹3,381.60 on 3 November 2026, down 29.3% from ₹4,780.60 a year earlier (31 October 2025) and down 32.3% over five years. Its highest weekly close since March 2016 was ₹7,351.45 on 6 September 2024. ### Sanofi India share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹2,772.80 | +22.0% |
| 1 month ago · 1 Oct 2026 | ₹3,037.40 | +11.3% |
| 6 months ago · 30 Apr 2026 | ₹3,407.20 | −0.8% |
| 1 year ago · 31 Oct 2025 | ₹4,780.60 | −29.3% |
| 3 years ago · 3 Nov 2023 | ₹4,680.15 | −27.7% |
| 5 years ago · 4 Nov 2021 | ₹4,993.08 | −32.3% |
| 10 years ago · 4 Nov 2016 | ₹2,635.01 | +28.3% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹2,694.48 | +25.5% |
| Highest weekly close since March 2016 · 6 Sep 2024 | ₹7,351.45 | −54.0% |
| Lowest weekly close since March 2016 · 8 Sep 2017 | ₹2,444.57 | +38.3% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹4,636.80 | −27.1% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹2,772.80 | +22.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Sanofi India? 5 Nov 2026: Coming up: ex-date for an interim dividend of ₹75 a share. 3 Nov 2026: Sanofi India closed at ₹3,381.60, up 22.0% on the week and up 11.3% on the month. ### Earlier

- Results for July to September 2026: Revenue up 3.6% and profit up 53.9% on a year earlier. - 5 Aug 2026: Sanofi India held its results call for April to June 2026. Management guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed. - 22 Apr 2026: ex-date for a dividend of ₹48 a share. - 7 Nov 2025: ex-date for an interim dividend of ₹75 a share. ## What dividend does Sanofi India pay? Sanofi India paid ₹123 a share in regular dividends in the 12 months to 4 November 2026 (2 payments), a yield of 3.64% at the ₹3,381.60 close on 3 November 2026. The last was a dividend of ₹48 a share, ex-date 22 April 2026. Next: ₹75 a share, ex-date 5 November 2026. ### Sanofi India dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 5 Nov 2026 (upcoming) | ₹75 | Interim | same day |
| 22 Apr 2026 | ₹48 | Dividend | same day |
| 7 Nov 2025 | ₹75 | Interim | same day |
| 25 Apr 2025 | ₹117 | Dividend | same day |
| 3 May 2024 | ₹117 | Dividend | same day |
| 7 Mar 2024 | ₹50 | Interim | same day |
| 28 Apr 2023 | ₹377 | Final + Special | n/a |
| 5 Aug 2022 | ₹193 | Special | 8 Aug 2022 |
| 12 Apr 2022 | ₹490 | Dividend + Special | n/a |
| 19 Apr 2021 | ₹365 | Dividend + Special | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Sanofi India Ltd paid out 87% of its profit as dividends in FY25, and it paid a dividend in each of its last 12 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Sanofi India management say on the latest results call? On the call for April to June 2026, held on 5 August 2026, Sanofi India's management guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed. > “I am not expecting that we will reach industry growth in 2026. For 2027, this is what we are evaluating right now.”
> Rachid Ayari, on the call for April to June 2026

### What management guided

- Partnership: industry growth not expected in 2026; recovery timing for 2027 remains under evaluation. - Insulin market: high-single-digit growth expected over time, with analogs sustaining double-digit growth despite GLP-1. - Exports: alternate-market offsets, Goa specialization and CMO insourcing to compensate mature-market losses. - CSR: 600,000-plus direct beneficiaries to be reached by year-end through KiDS, Diabetes in Schools and mobile units. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/365/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 5 August 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Sanofi India's next results? When Sanofi India reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Partnership growth: check whether OAD momentum broadens into CV and CNS after partner reorganization. - What to check (from the call)
- Partnership growth: check whether OAD momentum broadens into CV and CNS after partner reorganization. - Insulin competition: check weekly treatment's impact on new initiation, intensification and the existing basal-patient base. - Exports: check whether alternate-market wins and Goa manufacturing offset Australian mature-product losses. - Operating discipline: check whether cost actions continue without impairing top-line projects or patient-access initiatives. ## Which stock lists is Sanofi India on? Sanofi India is on 2 of our India lists: Dividend stocks and Pharma stocks. - [Dividend stocks Regular dividend yield (%): 3.67](https://www.sectoralpha.in/dividend-stocks-india)
- [Pharma stocks Market value (₹ crore): 7714.545176492619](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Sanofi India profitable? Sanofi India Ltd earned ₹117 Cr of net profit in the Sep 2026 quarter, +53.9% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was ₹327 Cr. Over 10 years profit has grown 0.2% a year on average. That is 23.8% of the quarter's revenue. The same quarter a year earlier earned ₹76.0 Cr. For the full year, FY25 profit was ₹327 Cr (−21.0% on the year before). Why profit moved: revenue changed +3.6% on a year earlier and the margin moved +5.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +7.0% and revenue −4.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Sanofi India make, and is it growing? Sanofi India Ltd reported ₹492 Cr of revenue in the Sep 2026 quarter, +3.6% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown −1.8% a year on average. The last full year, FY25, came in at ₹1,837 Cr. The last four reported quarters add to ₹1,822 Cr. FY25 revenue was ₹1,837 Cr, −8.7% on the year before. Recent pace: the last four quarters grew −4.7% on average, against −1.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −5.7%, against −3.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +2.5%, against −10.8% a year (accelerating). ## How much of every ₹100 of sales does Sanofi India keep? Sanofi India Ltd's operating margin was 33.0% in the Sep 2026 quarter, 5.0 percentage points higher than the same quarter a year ago. Across 12 years it has been between 17.0% and 28.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +4.6 percentage points on the year while gross margin changed +2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Sanofi India's profit turning into cash? Over the last 3 years, 84% of Sanofi India Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in ₹438 Cr of operating cash against ₹327 Cr of profit. After ₹23.0 Cr of spending on assets, ₹415 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 84% of profit came in as cash: the cash cycle got 50 days longer between FY20 and FY25, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Sanofi India's cash go? Sanofi India Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 83 days in FY25, up from 33 days in FY20. It spent ₹100 Cr on assets over the last 3 years. Customers take 35 days to pay, and stock sits for 127 days on average. At FY25 sales of ₹1,837 Cr, each day of that cycle ties up about ₹5.0 Cr, so roughly ₹418 Cr is tied up in the business at any time. FY25: customers took 35 days to pay and stock sat for 127 days, about 4.2 months of sales sitting as stock, for a full cycle of 83 days, longer than FY20's 33. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 127 days. Customers pay about 35 days after that. Suppliers are paid at 79 days. Together that makes the 83-day cycle. Spending on assets: ₹100 Cr over the last 3 years, against ₹114 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹12.0 Cr (FY25): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Sanofi India's P/E ratio, and how does it compare with its own history? Sanofi India Ltd's P/E is 21.3×, in the middle of its own history: higher than 44% of past readings. Its usual P/E (the middle reading) is 22.0×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −21.0% while the price moved −29.3%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −7.5% a year; about −9.6% a year came from earnings growth and about +2.1 percentage points from the multiple (the market paying more); over 10 years the price moved +2.5% a year; about +1.2% a year came from earnings growth and about +1.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Sanofi India business getting better or worse? Sanofi India Ltd's business is getting better. Profit growth hit its low 6 quarters ago at −31.5% and has recovered to +2.5%, with ROCE rising at 59.5%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Sanofi India earn on its capital? Sanofi India Ltd earned a ROCE of 58% in FY25. That is up from a low of 22% in FY14. Its return on capital used (ROIC) is 62.5 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 17.8% net margin and 1.46× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 17.8% net margin × 1.46× asset turnover × 1.68× leverage (assets divided by equity) ≈ 43.7% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 74.5% − 12.0% = +62.5 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 74.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 60.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Sanofi India have too much debt? Sanofi India Ltd has total debt of ₹15.0 Cr against shareholder equity of ₹826 Cr as of Sep 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.01 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Sanofi India shareholding pattern? Domestic institutions cut their stake in Sanofi India Ltd by 3.2 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 19.4% of the company. Promoters moved +0.0 points over the same period, to 60.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: −3.2 points over 8 quarters, to 19.4%; Promoters: +0.0 points over 8 quarters, to 60.4%; Foreign institutions: +0.0 points over 8 quarters, to 5.7%. Why the owners changed: domestic institutions drove it (−3.2 points). They reduced their stake. ## How far is Sanofi India from balance-sheet trouble? For Sanofi India Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Sanofi India rank in its industry? 47.9 out of 100, rank 6 of 8 in Pharma - MNC bulk Drugs, with 100% of the evidence available. Sanofi India Ltd scores 47.9 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 6. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 14.6 + 15.6 + 7.4 + 10.3 = 47.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Sanofi India compared with? Sanofi India ranks 6 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 47.9 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. Sanofi India Ltd this page SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Sanofi India in size? Sanofi India is the 7th largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Glaxosmithkline Pharmaceuticals, Pfizer, Astrazeneca Pharma India, Procter & Gamble Health and Sanofi Consumer Healthcare India. Just below it: Novartis India. ### Pharma - MNC bulk Drugs companies close in size

1. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
2. [Pfizer Ltd](https://www.sectoralpha.in/stocks/pfizer-ltd) ₹16,871 crore
3. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
4. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
5. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
6. Sanofi India Ltd ₹7,379 crore
7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) ₹4,179 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [Paisalo Digital Ltd](https://www.sectoralpha.in/stocks/paisalo-digital-ltd) ₹7,392 crore · Finance - Capital Markets - Brokers
2. [Cello World Ltd](https://www.sectoralpha.in/stocks/cello-world-ltd) ₹7,391 crore · Opalware
3. Sanofi India Ltd ₹7,379 crore
4. [Raymond Ltd](https://www.sectoralpha.in/stocks/raymond-ltd) ₹7,324 crore · Realty - Construction & Contracting
5. [Religare Enterprises Ltd](https://www.sectoralpha.in/stocks/religare-enterprises-ltd) ₹7,321 crore · Finance - Insurance

## What else do people ask about Sanofi India? ### What is Sanofi India's share price today? Sanofi India Ltd's share price is ₹3,381.60, −29.3% over the past year. The whole company is worth ₹7,788 Cr on the market. In the last 52 weeks it traded between ₹2,773 to ₹4,637; today it is 33% of the way up from the low, 3.7% below its 200-day average (as of 3 November 2026). ### What were Sanofi India's latest quarterly results? Sanofi India Ltd reported revenue of ₹492 Cr and net profit of ₹117 Cr for the Sep 2026 quarter. Revenue rose 3.6% and profit rose 53.9% compared with a year earlier. Earnings per share were ₹50.74. The operating margin was 33.0%, 5.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Sanofi India's market cap? Sanofi India Ltd's market capitalisation is ₹7,788 Cr at a share price of ₹3,381.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Sanofi India performing? Sanofi India Ltd's share price has been falling for 64 weeks. In its latest quarter, revenue rose 3.6% and profit rose 53.9% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Sanofi India's share price go up? This page does not forecast Sanofi India Ltd's share price. What it shows instead: the share price is ₹3,381.60, and it has been falling for 64 weeks. Its P/E of 21.3× is higher than 44% of its own last 10 years (as of 3 November 2026). ### Who owns Sanofi India? Promoters own 60.4% of Sanofi India Ltd, foreign institutions 5.7%, domestic institutions 19.4% and the public 14.5% (latest quarter). The biggest change over the last two years: Domestic institutions cut their stake by 3.2 percentage points over 8 quarters (as of 3 November 2026). ### Does Sanofi India have too much debt? No, Sanofi India Ltd has little debt: its debt is 0.02× its equity, and its operating profit is more than 100 times its interest bill. FY25 borrowings were ₹18.0 Cr against equity of ₹749 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Sanofi India in its business cycle? Sanofi India Ltd's FY25 operating margin was 27.0%, against a 12-year range of 17.0% to 28.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 33.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Sanofi India story? The main question: domestic institutions moved −3.2 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Sanofi India a stock worth studying right now? What the numbers show: Sanofi India Ltd's share price has fallen more than its earnings. Earnings per share fell 21.0% in a year while the price moved −29.3%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Sanofi India share price forecast for 2026? What management itself guided: Diabetes: H2 execution to continue across public-sector access, patient support and technology, with no growth rate committed. ## Lists

- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.